X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (239) 239
index medicus (233) 233
irreversible inhibitors (189) 189
growth-factor receptor (138) 138
chemistry, medicinal (129) 129
oncology (108) 108
egfr (107) 107
receptor, epidermal growth factor - antagonists & inhibitors (106) 106
tyrosine kinase inhibitors (106) 106
acquired-resistance (104) 104
animals (98) 98
protein kinase inhibitors - pharmacology (93) 93
cell lung-cancer (87) 87
cancer (86) 86
gefitinib (86) 86
cell line, tumor (77) 77
irreversible inhibitor (75) 75
pharmacology & pharmacy (73) 73
tyrosine kinase (73) 73
mutation (72) 72
biochemistry & molecular biology (71) 71
antineoplastic agents - pharmacology (70) 70
protein kinase inhibitors - chemistry (67) 67
receptor, epidermal growth factor - metabolism (66) 66
structure-activity relationship (65) 65
lung neoplasms - drug therapy (64) 64
tyrosine kinase inhibitor (57) 57
carcinoma, non-small-cell lung - drug therapy (55) 55
chemistry, organic (55) 55
tyrosine (55) 55
epidermal growth factor (52) 52
drug design (51) 51
lung cancer (48) 48
molecular structure (48) 48
antineoplastic agents - chemistry (47) 47
epidermal growth factor receptor (46) 46
protein kinase inhibitors - therapeutic use (46) 46
quinazolines - pharmacology (46) 46
receptor, epidermal growth factor - genetics (46) 46
female (45) 45
analysis (44) 44
antineoplastic agents - therapeutic use (44) 44
lung cancer, non-small cell (44) 44
mice (43) 43
erlotinib (42) 42
resistance (42) 42
cell proliferation - drug effects (41) 41
models, molecular (39) 39
mutations (39) 39
tumors (39) 39
lung neoplasms - genetics (36) 36
drug discovery (35) 35
quinazolines - chemistry (35) 35
afatinib (34) 34
antitumor-activity (33) 33
phase-ii trial (33) 33
design (32) 32
discovery (32) 32
kinases (32) 32
neoplasms - drug therapy (32) 32
potent (32) 32
open-label (31) 31
antineoplastic agents - chemical synthesis (30) 30
biological evaluation (30) 30
carcinoma, non-small-cell lung - genetics (30) 30
protein kinase inhibitors - chemical synthesis (30) 30
chemistry, multidisciplinary (29) 29
chemotherapy (29) 29
drug resistance, neoplasm (29) 29
inhibitors (29) 29
lung-cancer (29) 29
t790m mutation (29) 29
enzyme inhibitors (28) 28
care and treatment (27) 27
1st-line treatment (26) 26
dose-response relationship, drug (26) 26
growth-factor-receptor (26) 26
receptor, erbb-2 - antagonists & inhibitors (26) 26
cysteine (25) 25
quinazolines - therapeutic use (25) 25
research (25) 25
drug resistance (24) 24
drug-resistance (24) 24
health aspects (24) 24
irreversible egfr (24) 24
male (24) 24
phosphorylation (24) 24
protein binding (24) 24
enzyme inhibitors - pharmacology (23) 23
lung neoplasms - pathology (23) 23
nsclc (23) 23
breast cancer (22) 22
egf receptor (22) 22
non-small cell lung cancer (22) 22
respiratory tract diseases (22) 22
activation (21) 21
breast-cancer (21) 21
drug resistance, neoplasm - genetics (21) 21
drug screening assays, antitumor (21) 21
erbb receptors - antagonists & inhibitors (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 07/2016, Volume 59, Issue 14, pp. 6671 - 6689
Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in... 
GROWTH-FACTOR RECEPTOR | IRREVERSIBLE INHIBITORS | IN-VITRO | GEFITINIB | CHEMISTRY, MEDICINAL | METHIONINE MUTANT | BIOLOGICAL EVALUATION | TYROSINE KINASE INHIBITOR | DRUG-RESISTANCE | MUTATIONS | THREONINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Rats, Wistar | Antineoplastic Agents - chemical synthesis | Humans | Molecular Conformation | Crystallography, X-Ray | Lung Neoplasms - pathology | Male | Structure-Activity Relationship | Benzimidazoles - chemistry | Nicotine - pharmacology | Dose-Response Relationship, Drug | Neoplasms, Experimental - pathology | Protein Kinase Inhibitors - chemistry | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Protein Kinase Inhibitors - chemical synthesis | Lung Neoplasms - enzymology | Benzimidazoles - chemical synthesis | Models, Molecular | Rats | Antineoplastic Agents - chemistry | Drug Discovery | Animals | Nicotine - chemical synthesis | Mice, Nude | Nicotine - analogs & derivatives | Nicotine - chemistry | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Neoplasms, Experimental - drug therapy | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Journal Article
by Lu, XY and Yu, L and Zhang, Z and Ren, XM and Smaill, JB and Ding, K
MEDICINAL RESEARCH REVIEWS, ISSN 0198-6325, 09/2018, Volume 38, Issue 5, pp. 1550 - 1581
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2008, Volume 105, Issue 6, pp. 2070 - 2075
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 05/2017, Volume 25, Issue 10, pp. 2713 - 2723
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 02/2019, Volume 29, Issue 4, pp. 591 - 596
Overexpression of EGFR and HER2 are observed in many breast, ovarian, colon and prostate cancers. The second and third generation irreversible EGFR/HER2 dual... 
Tyrosine kinase | Dual inhibitor | Antitumor | Quinazoline | HER2 | Anticancer | Irreversible | EGFR | CHEMISTRY, MEDICINAL | CHEMISTRY, ORGANIC | RECEPTOR | EGFR-TKI | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | BREAST-CANCER | RESISTANCE | EXPRESSION | Tyrosine | Care and treatment | Analysis | Nuclear nonproliferation | Prostate cancer | Drug approval | Cancer
Journal Article
Lung Cancer, ISSN 0169-5002, 12/2018, Volume 126, pp. 149 - 155
Non-small cell lung cancers (NSCLCs) that harbor activating mutations for epidermal growth factor receptor ( ) show remarkable initial response to... 
Ba/F3 models | Osimertinib | Acquired resistance | Personalized therapy |